A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing response rates of almost 50% with 20% complete responses, and offers the ...

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly severe chronic graft-vs-host disease (cGVHD) in the AGAVE-201 trial, with ...

There are two kinds: chronic (cGvHD) and acute (aGvHD). Chronic graft versus host disease can be treated, but treatment can take months or years. What Is Chronic Graft Versus Host Disease (cGvHD)?

The patent, entitled Diagnostic method for detecting the pathological correlates of chronic graft-versus-host disease (cGvHD) using particular cytokine or chemokine biomarkers, has been submitted ...

All patients received myeloablative conditioning. The trial’s primary endpoint measured survival free of cGVHD, a possible transplant complication in which the donor's immune cells attack the ...

Sergio A. Giralt, MD, discusses how he uses cyclophosphamide to treat patients with chronic graft-vs-host disease (cGVHD), particularly in specific cases where other therapies may not be effective.

Orca-T significantly improved cGVHD-free survival compared to allo-HSCT, with a 78% vs 38% rate at one year. The study reported a 94% overall survival rate for Orca-T, with no new safety concerns ...

While HCT can be curative, it comes with significant risks. One major complication is chronic graft-versus-host disease (cGVHD), which affects up to 30-50% of long-term survivors. This condition ...

Wednesday, the drug received an FDA approval under the brand name Niktimvo to treat chronic GVHD (cGVHD) in patients who’ve failed at least two prior lines of systemic therapy. Based on the drug ...

The drug is already approved for treating cGVHD in adults. Please note that this is the 12th FDA approval secured by both AbbVie and J&J for Imbruvica. The approval also makes Imbruvica the first ...

BioSenic expects to use the proceeds from anticipated future fundraising as a priority to progress its Phase 3 clinical trial in cGvHD. Mont-Saint-Guibert, Belgium, June 6, 2024, 9:00pm CEST ...